A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

ID#: NCT06091254

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: Phase 3

Recruitment Status: Recruiting

Start Date: December 12, 2023

End Date: April 03, 2029

Contact Information:
Clinical Trials Administrator
844-734-6643
Summary: This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is. The aim of Part 2 of the study is to see how the study drug works compared to rituximab and chemotherapy (the current standard of care for NHL). Standard of care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: - What side effects may happen from taking the study drug - How much study drug is in your blood at different times - Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) - The impact from the study drug on your quality of life and ability to complete routine daily activities.
Eligibility: Key

Inclusion Criteria:

1. Diagnosis of cluster of differentiation 20^+ (CD20^+) FL Grade 1-3a, stage II bulky or stage III / IV

2. Need for treatment as described in the protocol

3. Have measurable disease on cross-sectional imaging documented by diagnostic imaging Computed tomography (CT) or Magnetic resonance imaging (MRI)

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

5. Adequate bone marrow function and hepatic function Key

Exclusion Criteria:

1. Central nervous system (CNS) lymphoma or leptomeningeal lymphoma

2. Histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma

3. Waldenström macroglobulinemia (WM, lymphoplasmacytic lymphoma), Grade 3b follicular lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma

4. Treatment with any systemic anti-lymphoma therapy

5. Infections and allergy/hypersensitivity to study drug or excipient NOTE: Other protocol defined inclusion / exclusion criteria apply
Find a Clinical Trial